Literature DB >> 15140896

Furin inhibition by compounds of copper and zinc.

Paul Podsiadlo1, Tomoko Komiyama, Robert S Fuller, Ofer Blum.   

Abstract

Furin, a human subtilisin-related proprotein convertase (SPC), is emerging as an important pharmaceutical target because it processes vital proteins of many aggressive pathogens. Furin inhibitors reported as yet are peptide derivatives and proteins, with the exception of andrographolides, which are natural compounds. Here we report that the small and highly stable compounds M(chelate)Cl(2) (M is copper or zinc) inhibit furin and Kex2, with Cu(TTP)Cl(2) and Zn(TTP)Cl(2) as the most efficient inhibitors. (TTP is 4'-[p-tolyl]-2,2 ':6',2"-terpyridine.) Inhibition is irreversible, competitive with substrate, and affected by substituents on the chelate. The free chelates are not inhibitors. Solvated Zn(2+) is less potent than its complexes. This is true also for copper and Kex2. However, solvated Cu(2+) (k(on) of 25,000 +/- 2,500 s(-1)) is more potent than Cu(TTP)Cl(2) (k(on) = 140 +/- 13 s(-1) and allows recovery of furin activity prior to a second inhibition phase. A mechanism that involves coordination to the catalytic histidine is proposed for all inhibitors. Target specificity is indicated by the fact that these metal chelate inhibitors are much less potent toward Kex2, the yeast homologue of furin. For example, k(on) with Zn(TTP)Cl(2) is 120 +/- 20 s(-1) for furin, but only 1.2 +/- 0.1 s(-1) for Kex2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140896     DOI: 10.1074/jbc.M400338200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.

Authors:  Mirella Vivoli; Thomas R Caulfield; Karina Martínez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

2.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

Review 3.  The biology of zinc transport in mammary epithelial cells: implications for mammary gland development, lactation, and involution.

Authors:  Nicholas H McCormick; Stephen R Hennigar; Kirill Kiselyov; Shannon L Kelleher
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-12-15       Impact factor: 2.673

4.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity.

Authors:  Julia M Coppola; Christin A Hamilton; Mahaveer S Bhojani; Martha J Larsen; Brian D Ross; Alnawaz Rehemtulla
Journal:  Anal Biochem       Date:  2007-01-17       Impact factor: 3.365

5.  Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.

Authors:  Guan-Sheng Jiao; Lynne Cregar; Jinzhi Wang; Sherri Z Millis; Cho Tang; Sean O'Malley; Alan T Johnson; Sina Sareth; Jason Larson; Gary Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-18       Impact factor: 11.205

Review 6.  Inhibitors of proprotein convertases.

Authors:  Ajoy Basak
Journal:  J Mol Med (Berl)       Date:  2005-10-08       Impact factor: 4.599

7.  Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine.

Authors:  Tomoko Komiyama; Joel A Swanson; Robert S Fuller
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Synthetic small-molecule prohormone convertase 2 inhibitors.

Authors:  Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2008-12-12       Impact factor: 4.436

9.  A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness.

Authors:  Julia M Coppola; Mahaveer S Bhojani; Brian D Ross; Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

Review 10.  Why All the Fury over Furin?

Authors:  Essam Eldin A Osman; Alnawaz Rehemtulla; Nouri Neamati
Journal:  J Med Chem       Date:  2021-08-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.